The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve
Latika Kohli1, Niroop Kaza, Nicholas J Lavalley
1Departments of Pathology, University of Alabama at Birmingham, WP P210, 619 South 19th St, Birmingham, AL 35294-0017, USA.
Abstract:
Malignant peripheral nerve sheath tumors (MPNSTs) are rapidly progressive Schwann cell neoplasms. The erbB family of membrane tyrosine kinases has been implicated in MPNST mitogenesis and invasion and, thus, is a potential therapeutic target. However, tyrosine kinase inhibitors (TKIs) used alone have limited tumoricidal activity. Manipulating the autophagy lysosomal pathway in cells treated with cytostatic agents can promote apoptotic cell death in some cases. The goal of this study was to establish a mechanistic basis for formulating drug combinations to effectively trigger death in MPNST cells. We assessed the effects of the pan erbB inhibitor PD168393 on MPNST cell survival, caspase activation, and autophagy. PD168393 induced a cytostatic but not a cytotoxic response in MPNST cells that was accompanied by suppression of Akt and mTOR activation and increased autophagic activity. The effects of autophagy modulation on MPNST survival were then assessed following the induction of chloroquine (CQ)-induced lysosomal stress. In CQ-treated cells, suppression of autophagy was accompanied by increased caspase activation. In contrast, increased autophagy induction by inhibition of mTOR did not trigger cytotoxicity, possibly because of Akt activation. We thus hypothesized that dual targeting of mTOR and Akt by PD168393 would significantly increase cytotoxicity in cells exposed to lysosomal stress. We found that PD168393 and CQ in combination significantly increased cytotoxicity. We conclude that combinatorial therapies with erbB inhibitors and agents inducing lysosomal dysfunction may be an effective means of treating MPNSTs.
Insights
Combining erbB inhibitors with lysosomal dysfunction agents shows promise for treating malignant peripheral nerve sheath tumors (MPNSTs). This approach enhances cell death, offering a potential new therapeutic strategy for MPNSTs.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell cancers.
- The erbB family of tyrosine kinases drives MPNST growth and invasion, making them a therapeutic target.
- Current tyrosine kinase inhibitors (TKIs) show limited efficacy as monotherapies.
Purpose of the Study:
- To investigate the mechanistic basis for combining therapies to induce cell death in MPNSTs.
- To assess the effects of the pan-erbB inhibitor PD168393 on MPNST cell survival, apoptosis, and autophagy.
- To evaluate the impact of lysosomal stress and autophagy modulation on MPNST cytotoxicity.
Main Methods:
- MPNST cells were treated with PD168393 to assess effects on survival, caspase activation, and autophagy.
- Autophagy was modulated using chloroquine (CQ) to induce lysosomal stress.
- Combined effects of PD168393 and CQ on MPNST cytotoxicity were evaluated.
Main Results:
- PD168393 induced cytostasis, suppressed Akt/mTOR, and increased autophagy in MPNST cells.
- CQ treatment suppressed autophagy, leading to increased caspase activation.
- Combination of PD168393 and CQ significantly enhanced MPNST cell cytotoxicity.
Conclusions:
- Dual targeting of erbB signaling and lysosomal pathways offers a potent strategy for MPNST treatment.
- Combinatorial therapy with PD168393 and CQ demonstrates significant cytotoxic effects.
- This study provides a rationale for developing combination therapies involving erbB inhibitors and lysosomal dysfunction agents for MPNSTs.
More Related Videos
07:10Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
